Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 10/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12179271 | 0.86 | ALK (0.46) | ALKHCRTR1HCRTR2 | |
| SCHEMBL14883177 | 0.80 | LMNA (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL14883242 | 0.79 | LMNA (0.43) | HCRTR1HCRTR2HTR2AHTR2C | |
| SCHEMBL12891570 | 0.77 | F2RL1 (0.57) | CYP1A2F2RL1 | |
| SCHEMBL12179281 | 0.76 | ALK (0.45) | ALKHCRTR1HCRTR2CYP1A2 | |
| SCHEMBL12179501 | 0.76 | ALK (0.45) | ALKHCRTR1HCRTR2CYP1A2 | |
| SCHEMBL2594661 | 0.76 | ALK (0.45) | ALKHCRTR1HCRTR2CYP1A2 | |
| SCHEMBL14883190 | 0.76 | HCRTR1 (0.43) | ALKHCRTR1HCRTR2 | |
| SCHEMBL14886152 | 0.76 | HCRTR1 (0.40) | HCRTR1HCRTR2CYP1A2 | |
| SCHEMBL14885650 | 0.75 | CYP19A1 (0.40) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020065613-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| US-9156819-B2 | 2-pyridyloxy-4-nitrile orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156819-B2 | 2-pyridyloxy-4-nitrile orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130102619-A1 | 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-04-25 | — | — | US | disclosed |
| US-20130102619-A1 | 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102619-A1 | 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NTSR2 | ALK 2481/4885HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.